Journal
CHEMMEDCHEM
Volume 12, Issue 2, Pages 106-119Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201600441
Keywords
ATP synthase; bedaquiline; multidrug resistance; Mycobacterium tuberculosis; pulmonary tuberculosis
Categories
Funding
- National Science and Technology Major Projects for Major New Drugs Innovation and Development (China) [2015ZX09102007-016-003]
- National High-tech R&D Program (China) [2012AA020302a]
- Wellcome Trust (UK) [WT110068/Z/15/Z]
Ask authors/readers for more resources
Bedaquiline (BDQ) is a novel and highly potent last-line antituberculosis drug that was approved by the US FDA in 2013. Owing to its stereo-structural complexity, chemical synthesis and compound optimization are rather difficult and expensive. This study describes the structural simplification of bedaquiline while preserving antitubercular activity. The compound's structure was split into fragments and reassembled in various combinations while replacing the two chiral carbon atoms with an achiral linkage instead. Four series of analogues were designed; these candidates retained their potent antitubercular activity at sub-microgram per mL concentrations against both sensitive and multidrug-resistant (MDR) Mycobacterium tuberculosis strains. Six out of the top nine MIC-ranked candidates were found to inhibit mycobacterial ATP synthesis activity with IC50 values between 20 and 40m, one had IC50>66m, and two showed no inhibition, despite their antitubercular activity. These results provide a basis for the development of chemically less complex, lower-cost bedaquiline derivatives and describe the identification of two derivatives with antitubercular activity against non-ATP synthase related targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available